What type of study is this?

August 22, 2025Malignancy SpectrumOpen Access

Pleural cavitations and pneumothorax following axitinib therapy in metastatic renal cell carcinoma: A case report

View Full Paper

Ask AI

Bookmark

Authors

FYFeride YılmazHacettepe University Hospital SYSerkan YaşarUniversity of Health Science FDFigen DemirkazıkHacettepe University

Discussion

Member takes

Implication

Case report reveals risks of pneumothorax and pleural cavitations in metastatic renal cell carcinoma patients treated with axitinib, indicating the need for vigilant monitoring.

Key Points

Pneumothorax developed in a 46-year-old male with mRCC after axitinib therapy, leading to serious complications.
The patient experienced recurrent pneumothorax and ultimately severe outcomes like sepsis and multiorgan failure.
Case presentation highlights how axitinib, a VEGFR inhibitor, can lead to rare complications in mRCC treatment.
Clinicians must monitor closely for potential cavitation-induced pneumothorax in patients undergoing axitinib therapy.

Cite This Study

Yılmaz et al. (2025) studied this question.

synapsesocial.com/papers/68af541fad7bf08b1eadb8db https://doi.org/10.1002/msp2.70014

View Full Paper

Ask AI

Bookmark

Implication

Case report reveals risks of pneumothorax and pleural cavitations in metastatic renal cell carcinoma patients treated with axitinib, indicating the need for vigilant monitoring.

Pleural cavitations and pneumothorax following axitinib therapy in metastatic renal cell carcinoma: A case report

Discussion

Member takes

Implication

Key Points

Cite This Study

Pleural cavitations and pneumothorax following axitinib therapy in metastatic renal cell carcinoma: A case report

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider